#USA #Irvine #PeproMene Bio #PMB-CT01 #ASH 2025

PeproMene Bio's Exceptional CAR T Therapy Data to Be Showcased at ASH 2025

PeproMene Bio, Inc., a clinical-stage biotechnology firm known for developing cutting-edge therapies for B-cell malignancies, has recently received acceptance for presenting two comprehensive studies on its promising CAR T therapy, PMB-CT01, at the upcoming 67th Annual Meeting of the American Society of Hematology (ASH) in December 2025.

Background of PMB-CT01

PMB-CT01 targets BAFF-R and represents a first-in-class cellular therapy designed to offer new hope to patients suffering from recurrent and refractory B-cell malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). This novel treatment has shown significant potential for patients who previously failed CD19-targeted therapies or presented with CD19-negative diseases.

Clinical Trial Highlights

Efficacy and Safety

In the ongoing Phase 1 clinical trials, preliminary data showcases the emerging safety and efficacy profile of PMB-CT01. Researchers have observed the following:

1. B-NHL Treatment Outcomes:
For patients with heavily pre-treated B-NHL, all seven patients in the initial cohort achieved a complete response (CR) within 1 to 3 months post-infusion, which includes those previously treated with CD19 CAR T therapy. Remarkably, even those with CD19-negative diseases responded positively. The remissions lasted beyond 32 months, with a median duration of 17 months at the data cutoff.

2. B-ALL Treatment Outcomes:
For the B-ALL cohort, out of six recruited patients, four achieved a complete remission (CR) which was undetectable for minimal residual disease (MRD). Among the patients who responded favorably, three had CD19-negative status at enrollment and successfully underwent allogeneic hematopoietic cell transplantation for a curative purpose. Importantly, no dose-limiting toxicities were encountered, with only one patient developing grade 2 cytokine release syndrome (CRS).

Presentation Details

Two key abstracts summarizing these findings will be presented at ASH 2025:

• - Title: "BAFFR-CAR T cells demonstrate durable responses and manageable toxicities in r/r B-cell lymphomas..."

Date/Time: December 6, 2:45 PM
Presenter: Elizabeth Budde, M.D., Ph.D.

• - Title: "BAFFR-CAR T cells show promising safety and anti-leukemia efficacy in r/r B-cell ALL patients..."

Date/Time: December 8, 11:00 AM
Presenter: Ibrahim Aldoss, M.D.

These presentations promise to shed light on the lasting impact of PMB-CT01 while underpinning the solid safety profile reported.

Concluding Remarks

Dr. Hazel Cheng, COO of PeproMene Bio, stated: "The consistent and lasting activity we've observed in both B-ALL and B-NHL, especially in patients who have exhausted CD19 CAR T options, strongly supports BAFF-R as a highly effective and safe alternative target. This data highlights PMB-CT01's potential to meet critical unmet needs in high-risk recurring diseases."

The ASH 2025 conference promises to be a pivotal moment for PeproMene Bio as it continues to pave the way for groundbreaking advancements in cellular therapies for B-cell malignancies. The anticipated presentations will not only share data but also instill hope in patients and healthcare providers seeking innovative treatment alternatives.